drugset / Trial / NCT02814643

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643

Phase 3 Completed 103 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindSupportive care

Summary

This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination

Timeline

Start
2016-07-01
Primary completion
2017-01-24
Completion
2017-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody Subcutaneous
Background Seasonal influenza virus vaccine Vaccine Intramuscular

Indications